Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): Final analysis of the MITO-2 randomized multicenter trial

被引：4
|
作者：
Pignata, S.
Scambia, G.
Savarese, A.
Sorio, R.
Breda, E.
Legge, F.
Gebbia, V.
Musso, P.
Gallo, C.
Perrone, F.
机构：
[1] MITO, Rome, Italy
[2] Ist Regina Elena, I-00161 Rome, Italy
[3] CRO, Aviano, Italy
[4] Osped Fatebenefratelli, Rome, Italy
[5] Univ Cattolica Sacro Cuore, Rome, Italy
[6] La Maddalena Clin, Palermo, Italy
[7] Osped M Ascoli ARNAS, Palermo, Italy
[8] Univ Naples 2, Naples, Italy
[9] Natl Canc Inst, Clin Trials Unit, Naples, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 18期
关键词：
D O I：
10.1200/jco.2010.28.18_suppl.lba5033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA5033
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III GCIG trial.
    Mahner, S.
    Meier, W.
    Du Bois, A.
    Brown, C.
    Lorusso, D.
    Ferrero, A.
    Cretin, J.
    Havsteen, H.
    Bessette, P.
    Angleitner-Boubenizek, L.
    Vergote, I. B.
    Vasey, P. A.
    Gebski, V.
    Slama, B.
    Herrstedt, J.
    Kaizer, L.
    Georgoulopoulos, A.
    Reed, N.
    Wagner, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] MITO (Multicentre Italian Trials in Ovarian cancer) - CERV 2 trial: a randomized phase II study of carboplatin and paclitaxel plus /- cetuximab, in advanced and/or recurrent cervical cancer
    Piccirillo, M. C.
    Scambia, G.
    Lorusso, D.
    De Giorgi, U.
    Nicoletto, M. O.
    Lauria, R.
    Mosconi, A.
    Sacco, C.
    Omarini, C.
    Tagliaferri, P.
    Ferrandina, G.
    Cinieri, S.
    Pisano, C.
    Cecere, S. C.
    Di Napoli, M.
    Salutari, V.
    Daniele, G.
    Gallo, C.
    Perrone, F.
    Pignata, S.
    ANNALS OF ONCOLOGY, 2015, 26 : 33 - 33
  • [33] Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group
    Lai, Chyong-Huey
    Vallikad, Elizabeth
    Lin, Hao
    Yang, Lan-Yan
    Jung, Shih-Ming
    Liu, Hsueh-Erh
    Ou, Yu-Che
    Chou, Hung-Hsueh
    Lin, Cheng-Tao
    Huang, Huei-Jean
    Huang, Kuan-Gen
    Qiu, Jiantai
    Hung, Yao-Ching
    Wu, Tzu-, I
    Chang, Wei-Yang
    Tan, Kien-Thiam
    Lin, Chiao-Yun
    Chao, Angel
    Chang, Chee-Jen
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2020, 31 (01)
  • [34] Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study
    Kurtz, J. E.
    Kaminsky, M. C.
    Floquet, A.
    Veillard, A. S.
    Kimmig, R.
    Dorum, A.
    Elit, L.
    Buck, M.
    Petru, E.
    Reed, N.
    Scambia, G.
    Varsellona, N.
    Brown, C.
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2011, 22 (11) : 2417 - 2423
  • [35] Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase III randomized trial
    Kosmidis, P
    Mylonakis, N
    Nicolaides, C
    Kalophonos, C
    Samantas, E
    Boukovinas, J
    Fountzilas, G
    Skarlos, D
    Economopoulos, T
    Tsavdaridis, D
    Papakostas, P
    Bacoyiannis, C
    Dimopoulos, M
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) : 3578 - 3585
  • [36] Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabin plus carboplatin (GC) or carboplatin plus pegylated doxorubicin (PLDC): A randomized phase III trial of the NOGGO-AGO-Germany-AGO Austria and GEICO-GCIG intergroup study (HECTOR).
    Sehouli, Jalid
    Meier, Werner
    Wimberger, Pauline
    Chekerov, Radoslav
    Belau, Antje
    Mahner, Sven
    Kurzeder, Christian
    Hilpert, Felix
    Klare, Peter
    Doerfel, Steffen
    Strauss, Hans-Georg
    Canzler, Ulrich
    Marth, Christian
    Reinthaller, Alexander
    Petru, Edgar
    Richter, Rolf
    Rubio, Maria Jesus
    Bover, Isabel
    Gonzalez-Martin, Antonio
    Harter, Philipp
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] Final analysis of weekly paclitaxel and weekly carboplatin (P) as first-line chemotherapy in 130 patients with advanced ovarian cancer (AOC).
    Sehouli, J
    Oskay-Oezcelik, G
    Camara, O
    Keil, E
    Ledwon, P
    Diedrich, K
    Elling, D
    Gebauer, G
    Christiansen, C
    Ortmann, O
    Lichtenegger, W
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 468S - 468S
  • [38] Comparison of pegylated liposomal doxorubicin and paclitaxel plus carboplatin-based chemotherapy as first line treatment for patients with ovarian cancer: a systematic review and meta-analysis of randomized controlled trials
    Shi, S-Q
    Jiang, F-F
    Hong, T.
    Zhuang, Y.
    Chen, L.
    Huang, X-L
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (06) : 2911 - 2927
  • [39] A RANDOMIZED PHASE II CLINICAL TRIAL OF THE SRC INHIBITOR SARACATINIB (AZD0530) AND CARBOPLATIN plus PACLITAXEL (C plus P) VERSUS C plus P IN PATIENTS (PTS) WITH ADVANCED PLATINUM-SENSITIVE EPITHELIAL OVARIAN CANCER (EOC)
    Poole, C.
    Lisyanskaya, A.
    Rodenhuis, S.
    Kristensen, G.
    Lauraine, E. Pujade
    Cantarini, M.
    Emeribe, U.
    Stuart, M.
    Coquard, I. Ray
    ANNALS OF ONCOLOGY, 2010, 21 : 304 - 305
  • [40] A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy/safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD) in women with low CA-125 platinum-sensitive ovarian cancer
    Herzog, Thomas
    Pignata, Sandro
    Ghamande, Sharad
    Rubio, Maria-Jesus
    Fujiwara, Keiichi
    Vulsteke, Christof
    Armstrong, Deborah
    Sehouli, Jalid
    Coleman, Robert
    Gabra, Hani
    Scambia, Giovanni
    Monk, Bradley
    Arija, Jose Angel
    Ushijima, Kimio
    Hanna, Rabbie
    Zamagni, Claudio
    Wenham, Robert
    Gonzalez-Martin, Antonio
    Slomovitz, Brian
    Jia, Yan
    Ramsay, Lisa
    Tewari, Krishnansu
    Weil, Susan
    Vergote, Ignace
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S38 - S39
12345